- Company
- Only Vemlidy’s sales grew in the ₩300B HBV drug mkt
- by Kim, Jin-Gu Aug 14, 2025 06:13am
- Korea's hepatitis B treatment market, which is valued at KRW 300 billion annually, is rapidly restructuring around Vemlidy (tenofovir alafenamide). Among original products, only Vemlidy is maintaining its growth, and in the generic market, only the Vemlidy series has shown a significant increase in sales. HBV treatment market reaches KRW
- Company
- 'Tevimbra' applies for reimbursement for five indications
- by Eo, Yun-Ho Aug 13, 2025 06:07am
- 'Tevimbra' is quickly expanding following its successful inclusion in the insurance reimbursement for esophageal cancer. BeOneMedicines Korea has been confirmed to have applied for reimbursement on the day of approval for five new indications for its PD-1 inhibitor immunotherapy Tevimbra (tislelizumab), which received additional approval
- Company
- Adult vaccination in a super-aged society highlighted
- by Whang, byung-woo Aug 13, 2025 06:07am
- South Korea has entered a super-aged society, with its population aged 65 and over exceeding 20%. The need for a response through adult vaccination is being emphasized. With the number of National Immunization Program (NIP) vaccines for adults limited to just influenza and pneumococcal vaccines, there is a growing opinion that the program nee
- Company
- Tariff impact inevitable for biodrugs’ export to the US
- by Cha, Jihyun Aug 12, 2025 06:16am
- Exports of domestically produced biopharmaceuticals to the US more than doubled last year compared to the previous year. If the Trump administration's tariffs on pharmaceuticals are implemented, the domestic biopharmaceutical export industry is expected to suffer significant damage. According to the “Key Data on the Domestic Biopharmaceutica
- Company
- 'Vanrafia' for rare kidney disease receives ODD in Korea
- by Eo, Yun-Ho Aug 12, 2025 06:16am
- A new drug for rare kidney disease, 'Vanrafia,' has been granted orphan drug designation in Korea. The Ministry of Food and Drug Safety (MFDS) recently announced this through notificiation board. The indication for the designation is to 'treat adult patients with primary immunoglobulin A nephropathy (IgAN) with a urine protein-to-creatin
- Company
- US Biosecurity Act passing is ramping up
- by Kim, Jin-Gu Aug 12, 2025 06:14am
- The U.S. Congress is re-pursuing the Biosecurity Act, which failed to pass last year. The bill explains a comprehensive set of sanctions against companies designated as 'biotechnology companies of concern.' Analysis suggests that the bill's chances of passing have increased, as it addresses the procedural issues that were a stumbling bl
- Company
- Gilead’s Livdelzi receives orphan drug designation in KOR
- by Eo, Yun-Ho Aug 11, 2025 06:05am
- The new primary biliary cholangitis drug ‘Livdelzi’ has received the orphan drug designation in Korea. The Ministry of Food and Drug Safety announced the news in a public notice on the 4th. Specifically, the designated indication is “the treatment of primary biliary cholangitis (PBC) in adults who have an inadequate response or intoler
- Company
- First TYK2i Sotyktu shows effect in Asian psoriasis patients
- by Son, Hyung Min Aug 11, 2025 06:04am
- The psoriatic arthritis treatment Sotyktu, which is jointly marketed in Korea by BMS Korea and Yuhan Corp, has established itself as a personalized oral treatment option for psoriatic arthritis patients in Korea, accumulating data from patients in East Asia. Sotyktu has been proven effective even in difficult-to-treat areas such as the scalp
- Company
- Plavix’s sales continue to grow 27 years into its release
- by Kim, Jin-Gu Aug 11, 2025 06:04am
- Sales of the original drug ‘Plavix’ continue to rise in its 27th year of release in the clopidogrel-based antiplatelet agent market. It has maintained its lead with a 23% market share in the annual KRW 550 billion market. Meanwhile, major generic products are showing signs of slowing down. Samjin Pharmaceutical's ‘Platless’ saw a decr
- Company
- The launch of Mounjaro is imminent
- by Moon, sung-ho Aug 11, 2025 06:03am
- The launch of Eli Lilly's 'Mounjaro,' which is called a 'miracle weight-loss drug' and garnered global attention alongside Wegovy, in Korea, is imminent. With the domestic launch of Mounjaro scheduled for mid-August, competition in the obesity treatment market, besides diabetes, is entering a new phase. There is significant interest in the
